| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
Tuxobertinib exhibits anti-proliferative action (IC50<100 nM) against the ERBB allosteric oncogene family and is a universal activator of this family of oncogenes [1].
|
|---|---|
| ln Vivo |
Tuxobertinib (0-100 mg/kg; sidewall; once daily given 15 days) indicated dose-effect tumor growth suppression and regression in athymic nude mice bearing HER2-labeled S310F Ba/F3 allograft tumors [1 ]. br/> Tuxobertinib (1-50 mg/kg. Facial once daily for 15 days) exhibited model-driven tumor growth inhibition and suppression in athymic nude mice harboring CUTO-14 PDX tumors expressing EGFR mutant EGFR ASV. fade[1].
|
| References | |
| Additional Infomation |
Tuxobertinib is a small molecule inhibitor with high oral bioavailability, irreversibility, and selectivity. It inhibits allosteric mutations in certain oncogenic driver genes, including those in the epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/neu or ErbB2), such as allosteric mutations in the extracellular domain of HER2 and insertion mutations in exon 20 of EGFR and HER2, exhibiting potential antitumor activity. After oral administration, tuxobertinib selectively binds to and inhibits these allosteric ErbB mutants without affecting wild-type EGFR, thereby selectively inhibiting tumor cell proliferation and angiogenesis in tumors expressing these allosteric ErbB mutations. EGFR and HER2, the ErbB receptor tyrosine kinases, are mutated or overexpressed in many tumor cell types and play a crucial role in tumor cell proliferation and tumor angiogenesis.
|
| Molecular Formula |
C29H29CLN6O4
|
|---|---|
| Molecular Weight |
561.031365156174
|
| Exact Mass |
560.19
|
| Elemental Analysis |
C, 62.08; H, 5.21; Cl, 6.32; N, 14.98; O, 11.41
|
| CAS # |
2414572-47-5
|
| PubChem CID |
154824631
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
40
|
| Complexity |
805
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HIBPKFXWOPYJPZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)
|
| Chemical Name |
N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide
|
| Synonyms |
BDTX-189; BDTX 189; BDTX189; EGFR/HER2 inhibitor BDTX-189; ErbB mutant-specific inhibitor BDTX-189; tuxobertinib
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~74.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.71 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7824 mL | 8.9122 mL | 17.8244 mL | |
| 5 mM | 0.3565 mL | 1.7824 mL | 3.5649 mL | |
| 10 mM | 0.1782 mL | 0.8912 mL | 1.7824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
